S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
AI Race Accelerates with Amazon's Investment In Anthropic
The "Plug and Play" Model Putting Online Giants to Shame (Ad)
Stock market today: World shares mixed after Wall Street retreat deepens
US consumer confidence tumbles in September as American anxiety about the future grows
Positive News SentimentPositive News
NASDAQ:SVRA

Savara (SVRA) Stock Forecast, Price & News

$3.70
-0.04 (-1.07%)
(As of 09/26/2023 ET)
Compare
Today's Range
$3.65
▼
$3.77
50-Day Range
$3.24
▼
$3.88
52-Week Range
$1.08
▼
$4.21
Volume
494,655 shs
Average Volume
425,024 shs
Market Capitalization
$500.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media

Savara MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
35.1% Upside
$5.00 Price Target
Short Interest
Healthy
2.68% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
$999,999 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.21 out of 5 stars

Medical Sector

648th out of 964 stocks

Pharmaceutical Preparations Industry

284th out of 438 stocks

See Top Rated MarketRank™ Stocks Here

SVRA stock logo

About Savara (NASDAQ:SVRA) Stock

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

SVRA Price History

SVRA Stock News Headlines

September 13, 2023 | seekingalpha.com
Molgramostim: Savara's Single Shot At Success
September 11, 2023 | finance.yahoo.com
Savara Inc.'s (NASDAQ:SVRA) Path To Profitability
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
September 5, 2023 | finance.yahoo.com
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 31, 2023 | msn.com
Savara (SVRA) Price Target Increased by 17.02% to 5.61
August 14, 2023 | msn.com
HC Wainwright & Co. Maintains Savara (SVRA) Buy Recommendation
August 11, 2023 | finance.yahoo.com
Savara Reports Second Quarter Financial Results and Provides Business Update
July 21, 2023 | benzinga.com
10% Owner of Savara Makes $999K Buy
September 27, 2023 | Wall Street Fundamentals (Ad)
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
July 20, 2023 | benzinga.com
Savara Recent Insider Activity
July 20, 2023 | benzinga.com
999K Reasons To Be Bullish On Savara Stock
July 16, 2023 | seekingalpha.com
Savara: A Speculative Play
July 13, 2023 | seekingalpha.com
Savara prices $80M common stock and pre-funded warrants offering
July 13, 2023 | marketwatch.com
Savara Shares Near 52-Week High After $80M Offering Prices
July 13, 2023 | marketwatch.com
Savara Prices Share Offering at $3 a Share
July 13, 2023 | finance.yahoo.com
Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
June 26, 2023 | msn.com
Savara joins Russell 3000
June 26, 2023 | finance.yahoo.com
Savara Completes Enrollment of Pivotal Phase 3 IMPALA-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
June 13, 2023 | markets.businessinsider.com
Analysts Are Bullish on Top Healthcare Stocks: Evolent Health (EVH), Savara (SVRA)
June 2, 2023 | finance.yahoo.com
Savara to Present at the Jefferies Healthcare Conference
May 28, 2023 | finance.yahoo.com
Independent Director of Savara David Ramsay Buys 4.8% More Shares
May 28, 2023 | finance.yahoo.com
Independent Director of Savara David Ramsay Buys 4.8% More Shares \
May 17, 2023 | msn.com
HC Wainwright & Co. Reiterates Savara (SVRA) Buy Recommendation
May 17, 2023 | markets.businessinsider.com
Savara (SVRA) Gets a Buy from H.C. Wainwright
May 16, 2023 | msn.com
Why Shares of Savara Jumped on Tuesday
May 16, 2023 | msn.com
Savara rises as Jefferies upgrades citing 100% upside
May 15, 2023 | finance.yahoo.com
Savara Reports First Quarter Financial Results and Provides Business Update
See More Headlines
Receive SVRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Savara and its competitors with MarketBeat's FREE daily newsletter.

SVRA Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SVRA
Previous Symbol
AMEX:ANX
CUSIP
N/A
CIK
1160308
Web
www.savarapharma.com
Phone
512-614-1848
Fax
858-552-0876
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+35.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.28)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-38,150,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.62%
Return on Assets
-31.81%

Debt

Debt-to-Equity Ratio
0.30
Current Ratio
18.33
Quick Ratio
18.33

Sales & Book Value

Annual Sales
$260,000.00
Price / Sales
1,923.57
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.95 per share
Price / Book
3.89

Miscellaneous

Outstanding Shares
135,170,000
Free Float
128,982,000
Market Cap
$500.13 million
Optionable
Optionable
Beta
0.89
Metaverse Stocks And Why You Can't Ignore Them Cover
Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Robert N. Neville (Age 51)
    Chairman of the Board, Chief Executive Officer
  • Taneli Jouhikainen (Age 51)
    President, Chief Operating Officer
  • David L. Lowrance (Age 50)
    Chief Financial Officer
  • Nevan C. Elam (Age 49)
    Independent Director
  • Richard J. Hawkins (Age 68)
    Independent Director
  • Joseph S. McCracken Ph.D. (Age 64)
    Independent Director
  • Matthew Pauls J.D.Matthew Pauls J.D. (Age 46)
    Independent Director
  • Yuri Pikover (Age 56)
    Independent Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SVRA Stock - Frequently Asked Questions

Should I buy or sell Savara stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Savara in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SVRA shares.
View SVRA analyst ratings or view top-rated stocks.

What is Savara's stock price forecast for 2023?

2 Wall Street research analysts have issued 12-month price objectives for Savara's stock. Their SVRA share price forecasts range from $4.00 to $6.00. On average, they expect the company's stock price to reach $5.00 in the next year. This suggests a possible upside of 35.1% from the stock's current price.
View analysts price targets for SVRA or view top-rated stocks among Wall Street analysts.

How have SVRA shares performed in 2023?

Savara's stock was trading at $1.55 at the start of the year. Since then, SVRA shares have increased by 138.7% and is now trading at $3.70.
View the best growth stocks for 2023 here.

When is Savara's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our SVRA earnings forecast.

How were Savara's earnings last quarter?

Savara Inc (NASDAQ:SVRA) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.01.

What other stocks do shareholders of Savara own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Savara investors own include BioLineRx (BLRX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Geron (GERN), Inovio Pharmaceuticals (INO), T2 Biosystems (TTOO), Verastem (VSTM), Agile Therapeutics (AGRX) and Corbus Pharmaceuticals (CRBP).

What is Savara's stock symbol?

Savara trades on the NASDAQ under the ticker symbol "SVRA."

Who are Savara's major shareholders?

Savara's stock is owned by many different retail and institutional investors. Top institutional shareholders include Caxton Corp (3.68%), BlackRock Inc. (4.29%), Jennison Associates LLC (2.34%), Geode Capital Management LLC (1.61%), State Street Corp (0.99%) and Northern Trust Corp (0.55%). Insiders that own company stock include Badrul A Chowdhury, David A Ramsay, David L Lowrance, Joseph S Mccracken, Matthew Pauls, Raymond Dennis Pratt and Rick Yang.
View institutional ownership trends.

How do I buy shares of Savara?

Shares of SVRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Savara's stock price today?

One share of SVRA stock can currently be purchased for approximately $3.70.

How much money does Savara make?

Savara (NASDAQ:SVRA) has a market capitalization of $500.13 million and generates $260,000.00 in revenue each year. The company earns $-38,150,000.00 in net income (profit) each year or ($0.28) on an earnings per share basis.

How can I contact Savara?

Savara's mailing address is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. The official website for the company is www.savarapharma.com. The company can be reached via phone at 512-614-1848, via email at ir@savarapharma.com, or via fax at 858-552-0876.

This page (NASDAQ:SVRA) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -